CRON
Get informed when a big investor buys or sells
+ FollowUndervalued by 63.2% based on the discounted cash flow analysis.
| Market cap | $1.73 Billion |
|---|---|
| Enterprise Value | $1.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 1.2 |
| Outstanding Shares | 385,306,213 |
| P/E Ratio | 17.26 |
|---|---|
| PEG | -9.54 |
| Price to Sales | - |
| Price to Book Ratio | 1.6 |
| Enterprise Value to Revenue | 4.95 |
| Enterprise Value to EBIT | 25.85 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2396▼ 14.80% |
|---|---|
| Total Calls | 1,156,200▼ 19.12% |
| Total Puts | 277,000▼ 50.00% |
Holdings and activity of institutional investors.
| Ownership % | 12.32%▼ 0.37% |
|---|---|
| Total Invested | $133.68M▲ 8.70% |
| Investors Holding | 206▲ 1.00% |
No data
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under...